Yunpeng Yang, Jianya Zhou, Jianying Zhou, Jifeng Feng, Wu Zhuang, Jianhua Chen, Jun Zhao, Wei Zhong, Yanqiu Zhao, Yiping Zhang, Yong Song, Yi Hu, Zhuang Yu, Youling Gong, Yuan Chen, Feng Ye, Shucai Zhang, Lejie Cao, Yun Fan, Gang Wu, Yubiao Guo, Chengzhi Zhou, Kewei Ma, Jian Fang, Weineng Feng, Yunpeng Liu, Zhendong Zheng, Gaofeng Li, Ning Wu, Wei Song, Xiaoqing Liu, Shijun Zhao, Lieming Ding, Li Mao, Giovanni Selvaggi, Xiaobin Yuan, Yuanqing Fu, Tao Wang, Shanshan Xiao, Li Zhang. Lancet Respir Med 2020
Times Cited: 66
Times Cited: 66
Lucio Crinò, Myung-Ju Ahn, Filippo De Marinis, Harry J M Groen, Heather Wakelee, Toyoaki Hida, Tony Mok, David Spigel, Enriqueta Felip, Makoto Nishio, Giorgio Scagliotti, Fabrice Branle, Chetachi Emeremni, Massimiliano Quadrigli, Jie Zhang, Alice T Shaw. J Clin Oncol 2016
Times Cited: 249
Times Cited: 249
List of shared articles
Times cited
Decoding the Evolutionary Response to Ensartinib in Patients With ALK-Positive NSCLC by Dynamic Circulating Tumor DNA Sequencing.
Yunpeng Yang, Jie Huang, Tao Wang, Jianya Zhou, Jing Zheng, Jifeng Feng, Wu Zhuang, Jianhua Chen, Jun Zhao, Wei Zhong,[...]. J Thorac Oncol 2021
Yunpeng Yang, Jie Huang, Tao Wang, Jianya Zhou, Jing Zheng, Jifeng Feng, Wu Zhuang, Jianhua Chen, Jun Zhao, Wei Zhong,[...]. J Thorac Oncol 2021
[Pharmacology and Clinical Evaluation of Ensartinib Hydrochloride Capsule].
Yang Wang, Xiaobin Yuan, Jiayan Xiong, Zhidong Hao, Xingzhe Peng, Wanlin Chen, Lingling Cui, Hua Li, Xiulan Wang, Xiangbo He,[...]. Zhongguo Fei Ai Za Zhi 2020
Yang Wang, Xiaobin Yuan, Jiayan Xiong, Zhidong Hao, Xingzhe Peng, Wanlin Chen, Lingling Cui, Hua Li, Xiulan Wang, Xiangbo He,[...]. Zhongguo Fei Ai Za Zhi 2020
Targeting ALK Rearrangements in NSCLC: Current State of the Art.
Ling Peng, Liping Zhu, Yilan Sun, Justin Stebbing, Giovanni Selvaggi, Yongchang Zhang, Zhentao Yu. Front Oncol 2022
Ling Peng, Liping Zhu, Yilan Sun, Justin Stebbing, Giovanni Selvaggi, Yongchang Zhang, Zhentao Yu. Front Oncol 2022
Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations.
David König, Spasenija Savic Prince, Sacha I Rothschild. Cancers (Basel) 2021
David König, Spasenija Savic Prince, Sacha I Rothschild. Cancers (Basel) 2021
Pharmacotherapeutic advances with anaplastic lymphoma kinase inhibitors for the treatment of non-small cell lung cancer.
Alice Indini, Erika Rijavec, Michele Ghidini, Claudia Bareggi, Donatella Gambini, Barbara Galassi, Paola Antonelli, Giulia Bettio, Clarissa Di Nubila, Francesco Grossi. Expert Opin Pharmacother 2020
Alice Indini, Erika Rijavec, Michele Ghidini, Claudia Bareggi, Donatella Gambini, Barbara Galassi, Paola Antonelli, Giulia Bettio, Clarissa Di Nubila, Francesco Grossi. Expert Opin Pharmacother 2020
Treatment Sequencing for Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer.
Diego Kauffmann-Guerrero, Kathrin Kahnert, Rudolf M Huber. Drugs 2021
Diego Kauffmann-Guerrero, Kathrin Kahnert, Rudolf M Huber. Drugs 2021
Overcoming TKI resistance in fusion-driven NSCLC: new generation inhibitors and rationale for combination strategies.
Alessandro Russo, Andrés F Cardona, Christian Caglevic, Paolo Manca, Alejandro Ruiz-Patiño, Oscar Arrieta, Christian Rolfo. Transl Lung Cancer Res 2020
Alessandro Russo, Andrés F Cardona, Christian Caglevic, Paolo Manca, Alejandro Ruiz-Patiño, Oscar Arrieta, Christian Rolfo. Transl Lung Cancer Res 2020
Toxicity profile of anaplastic lymphoma kinase tyrosine kinase inhibitors for patients with non-small cell lung cancer: A systematic review and meta-analysis.
Yunxia Tao, Yu Zhou, Le Tang, Haizhu Chen, Yu Feng, Yuankai Shi. Invest New Drugs 2022
Yunxia Tao, Yu Zhou, Le Tang, Haizhu Chen, Yu Feng, Yuankai Shi. Invest New Drugs 2022
Emerging Systemic Treatment Perspectives on Brain Metastases: Moving Toward a Better Outlook for Patients.
Christopher Alvarez-Breckenridge, Jordi Remon, Yolanda Piña, Edwin Nieblas-Bedolla, Peter Forsyth, Lizza Hendriks, Priscilla K Brastianos. Am Soc Clin Oncol Educ Book 2022
Christopher Alvarez-Breckenridge, Jordi Remon, Yolanda Piña, Edwin Nieblas-Bedolla, Peter Forsyth, Lizza Hendriks, Priscilla K Brastianos. Am Soc Clin Oncol Educ Book 2022
Systematic Review and Network Meta-Analysis of Anaplastic Lymphoma Kinase (ALK) Inhibitors for Treatment-Naïve ALK-Positive Lung Cancer.
Cheng-Hao Chuang, Hsiao-Ling Chen, Hsiu-Mei Chang, Yu-Chen Tsai, Kuan-Li Wu, I-Hua Chen, Kung-Chao Chen, Jui-Ying Lee, Yong-Chieh Chang, Chin-Ling Chen,[...]. Cancers (Basel) 2021
Cheng-Hao Chuang, Hsiao-Ling Chen, Hsiu-Mei Chang, Yu-Chen Tsai, Kuan-Li Wu, I-Hua Chen, Kung-Chao Chen, Jui-Ying Lee, Yong-Chieh Chang, Chin-Ling Chen,[...]. Cancers (Basel) 2021
Lorlatinib Should Be Considered as the Preferred First-Line Option in Patients With Advanced ALK-Rearranged NSCLC.
Misako Nagasaka, Sai-Hong Ignatius Ou. J Thorac Oncol 2021
Misako Nagasaka, Sai-Hong Ignatius Ou. J Thorac Oncol 2021
[Recommendations from Experts in the Management of Adverse Reactions
to ALK Inhibitors (2021 Version)].
Ke Wang, Juan Li, Jianguo Sun, Li Li, Xi Zhang, Jianyong Zhang, Min Yu, Xianwei Ye, Ming Zhang, Yu Zhang,[...]. Zhongguo Fei Ai Za Zhi 2021
Ke Wang, Juan Li, Jianguo Sun, Li Li, Xi Zhang, Jianyong Zhang, Min Yu, Xianwei Ye, Ming Zhang, Yu Zhang,[...]. Zhongguo Fei Ai Za Zhi 2021
The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer.
Valerio Gristina, Maria La Mantia, Federica Iacono, Antonio Galvano, Antonio Russo, Viviana Bazan. Pharmaceuticals (Basel) 2020
Valerio Gristina, Maria La Mantia, Federica Iacono, Antonio Galvano, Antonio Russo, Viviana Bazan. Pharmaceuticals (Basel) 2020